Material profile
Survodutide, also known as BI 456906, is described in published research as a dual agonist at GLP-1 and glucagon receptors. This receptor profile differs from GIP/GLP-1 combinations.
Specification and contents
Each box contains 10 unlabelled vials with 10 mg of Survodutide each, 100 mg total per box. Product identification appears only on the outer kit packaging.
The labelled single vial in the product image is illustrative. The selected variant and outer kit packaging determine product identification.
Research context
The cited primary paper characterizes BI 456906 in cellular and preclinical models as a GCGR/GLP-1R dual agonist. This classification does not replace testing of the supplied lot or establish a medical claim. PubMed: Primary source.
Catalog context
Further products for catalog context: Tirzepatide. For research use only, not for human or animal use.